1-8 of 8
Manish R. Sharma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Pamela N. Munster, Andrew E. Greenstein, Gini F. Fleming, Erkut Borazanci, Manish R. Sharma, Joseph M. Custodio, Iulia Cristina Tudor, Hristina I. Pashova, Stacie Peacock Shepherd, Andreas Grauer, Jasgit C. Sachdev
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3214–3224.
https://doi.org/10.1158/1078-0432.CCR-21-4363
Published: 02 August 2022
View article titled, Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Open the PDF for Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R. Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4511–4520.
https://doi.org/10.1158/1078-0432.CCR-20-3757
Published: 15 August 2021
View article titled, First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Open the PDF for First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response

Manish R. Sharma, Smita S. Joshi, Hedy L. Kindler
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3890.
https://doi.org/10.1158/1078-0432.CCR-20-1219
Published: 15 July 2020
View article titled, 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response
Open the PDF for 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response in another window
Journal Articles

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing

Smita S. Joshi, Daniel V.T. Catenacci, Theodore G. Karrison, Jaclyn D. Peterson, Mark M. Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J. Picozzi, Andrea Amico, Robert Marsh, Mark F. Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 18–24.
https://doi.org/10.1158/1078-0432.CCR-19-1483
Published: 03 January 2020
View article titled, Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <em>UGT1A1</em> Genotype–Guided Dosing
Open the PDF for Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using <em>UGT1A1</em> Genotype–Guided Dosing in another window
Includes: Supplementary data
Journal Articles

Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Giuseppe Toffoli, Manish R. Sharma, Elena Marangon, Bianca Posocco, Elizabeth Gray, Quan Mai, Angela Buonadonna, Blase N. Polite, Gianmaria Miolo, Gianna Tabaro, Federico Innocenti
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 918–924.
https://doi.org/10.1158/1078-0432.CCR-16-1012
Published: 14 February 2017
View article titled, Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Open the PDF for Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials

Manish R. Sharma, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 527–529.
https://doi.org/10.1158/1078-0432.CCR-15-2005
Published: 31 January 2016
View article titled, Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials
Open the PDF for Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials in another window
Journal Articles

Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients

Manish R. Sharma, Theodore G. Karrison, Bethany Kell, Kehua Wu, Michelle Turcich, David Geary, Soonmo P. Kang, Naoko Takebe, Richard A. Graham, Michael L. Maitland, Richard L. Schilsky, Mark J. Ratain, Ezra E.W. Cohen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3059–3067.
https://doi.org/10.1158/1078-0432.CCR-12-3829
Published: 30 May 2013
View article titled, Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients
Open the PDF for Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients in another window
Journal Articles

Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

Manish R. Sharma, Theodore G. Karrison, Yuyan Jin, Robert R. Bies, Michael L. Maitland, Walter M. Stadler, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2309–2315.
https://doi.org/10.1158/1078-0432.CCR-11-1815
Published: 16 April 2012
View article titled, Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
Open the PDF for Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints in another window
Includes: Supplementary data